Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:50:11 EDT Tue 15 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:OTLK from 2025-09-16 to 2026-09-15 - 34 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-09-11 07:00U:OTLKNews ReleaseOutlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
2026-09-10 09:10U:OTLKNews ReleaseOutlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA(TM) in Virtual Investor CEO Connect Segment
2026-08-27 16:05U:OTLKNews ReleaseOutlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA(TM)
2026-08-27 09:01U:OTLKNews ReleaseOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-14 07:15U:OTLKNews ReleaseOutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA(TM)
2026-08-12 21:45U:OTLKNews ReleaseOutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
2026-08-12 16:01U:OTLKNews ReleaseOutlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
2026-08-06 08:45U:OTLKNews ReleaseOutlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
2026-07-24 14:40U:OTLKNews ReleaseOutlook Therapeutics Announces LYTENAVA(TM) FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
2026-06-16 08:02U:OTLKNews ReleaseOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) as a Treatment for Wet AMD
2026-06-01 08:46U:OTLKNews ReleaseOutlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-28 16:00U:OTLKNews ReleaseOutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-05-26 07:00U:OTLKNews ReleaseOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-05-15 16:05U:OTLKNews ReleaseOutlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-04-23 16:05U:OTLKNews ReleaseOutlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
2026-04-22 08:30U:OTLKNews ReleaseOutlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2026-04-21 09:05U:OTLKNews ReleaseOutlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-04-07 08:50U:OTLKNews ReleaseOutlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) Accepted by FDA
2026-03-25 16:05U:OTLKNews ReleaseOutlook Therapeutics Announces Closing of $5.0 Million Public Offering
2026-03-24 07:00U:OTLKNews ReleaseOutlook Therapeutics Announces Pricing of $5.0 Million Public Offering
2026-03-23 17:30U:OTLKNews ReleaseOutlook Therapeutics Announces Proposed Public Offering
2026-03-16 08:05U:OTLKNews ReleaseOutlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
2026-03-05 16:15U:OTLKNews ReleaseOutlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)
2026-02-19 09:00U:OTLKNews ReleaseOutlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA(TM) (bevacizumab gamma) in Switzerland
2026-02-17 08:05U:OTLKNews ReleaseOutlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-02-11 08:45U:OTLKNews ReleaseOutlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
2026-01-06 08:35U:OTLKNews ReleaseOutlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
2025-12-31 16:15U:OTLKNews ReleaseOutlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD
2025-12-26 17:00U:OTLKNews ReleaseOutlook Therapeutics Announces New Employment Inducement Grants
2025-12-19 08:05U:OTLKNews ReleaseOutlook Therapeutics Reports Financial Results for Fiscal Year 2025
2025-11-24 09:05U:OTLKNews ReleaseOutlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
2025-11-13 08:30U:OTLKNews ReleaseOutlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
2025-11-03 08:35U:OTLKNews ReleaseOutlook Therapeutics Re-Submits Biologics License Application for ONS-5010
2025-09-29 08:45U:OTLKNews ReleaseOutlook Therapeutics Provides Update on Type A Meeting with FDA